Anaconda Biomed Secures $56 Million to Advance Thrombectomy Portfolio and ATHENA Pivotal Trial
Anaconda Biomed, a Spanish medical technology company developing a next-generation portfolio of thrombectomy catheters based on its core funnel catheter technology platform, has announced the closing of a $56 million financing led by Omega Funds, alongside new investor Spain’s Co-investment Fund managed by COFIDES, with continued participation from Asabys Sabadell Asabys II, Ysios Capital, and CDTI through its SICC Innvierte program.
Proceeds will support product development and clinical work, including completion of the ongoing ATHENA pivotal IDE study, a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter. Anaconda’s proprietary Funnel Catheter platform is designed to improve clot capture, reduce embolic complications, and maximize brain reperfusion. By combining aspiration power with flow-arrest and flow-reversal, the platform may address clot retrieval, fragmentation, and downstream embolization, taking on thrombectomy’s most persistent challenges. The company’s product portfolio will include supplementary tools such as stent retrievers, sheaths, and guidewires designed to complement the funnel catheter technology.
Anaconda targets a large, underpenetrated, and expanding stroke intervention market. Strokes cause seven million deaths annually, most of which are ischemic strokes, with 30% of these patients treated using mechanical thrombectomy, translating to nearly 270,000 procedures globally in 2026. The company has established a production facility on the edge of Barcelona, where direct control of key development and manufacturing processes provides efficient and iterative product expansion capabilities, and is establishing meaningful manufacturing trade secrets associated with its core technology.
Trent Reutiman, Chief Executive Officer of Anaconda Biomed, said the latest funding round allows the company to further advance its work in the acute treatment of patients suffering a stroke, with the goal of reducing disability and death caused by large vessel occlusive disease. Reutiman noted that the support of this leading group of investors reflects growing confidence in the company’s technology platform, and that the funds raised will ensure the company has the resources to complete clinical and regulatory requirements.
Claudio Nessi, Managing Director of Omega Funds, said Anaconda is bringing a next-generation solution to the large and growing ischemic stroke market. Nessi noted that for millions of patients around the world, its portfolio of products offers hope for better treatment outcomes, and that with a strong team led by Reutiman, Anaconda has the resources and unique technology to establish itself in the active interventional neurovascular device market.
